Effects of l-tetrahydropalmatine on locomotor sensitization to oxycodone in mice

Acta Pharmacologica Sinica

Volumn 26, Issue 5, 2005, Pages 533-538

  Liu, Yan Li ^a,b   Liang, Jian Hui ^c   Yan, Ling Di ^a   Su, Rui Bin ^a   Wu, Chun Fu ^b   Gong, Ze Hui ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

L tetrahydropalmatine; Locomotor sensitization; Oxycodone

Indexed keywords

CALCIUM CHANNEL L TYPE; OPIATE AGONIST; OXYCODONE; TETRAHYDROPALMATINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHINESE HERB; CONTROLLED STUDY; DRUG EFFECT; HYPERACTIVITY; LOCOMOTION; MOTOR PERFORMANCE; MOUSE; MUSCULOSKELETAL SYSTEM; NEUROTRANSMITTER RELEASE; NONHUMAN; PLACE PREFERENCE; SENSITIZATION; WITHDRAWAL SYNDROME;

ANIMALS; BERBERINE ALKALOIDS; CORYDALIS; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MOTOR ACTIVITY; OXYCODONE; PLANTS, MEDICINAL; RECEPTORS, OPIOID;

EID: 18744384989     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00101.x     Document Type: Article

References (29)

1. Spyraki C, Fibinger HC, Phillips AG. Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology 1983; 79: 278-83.
2. De Vries TJ, Schoffelmeer AN, Binnekade R, Mulder AH, Vanderschuren LJ. Drug-induced reinstatement of heroin- and cocaine-seeking behaviour following long-term extinction is associated with expression of behavioural sensitization. Eur J Neurosci 1998; 10: 3565-71.
3. Kalivas PW, Pierce RC, Cornish J, Sorg BA. A role for sensitization in craving and relapse in cocaine addiction. J Psychopharmacol 1998; 12: 49-53.
4. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of drug addiction. Brain Res Brain Res Rev 1993; 18: 247-91.
5. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 2000; 95: S91-117.
6. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47: 639-46.
7. Glare PA, Walsh TD. Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol 1993, 11: 973-8.
8. Mather LE. Analgesic drug. In: Anaesthesia. Nimmo WS, Smith G, editors. Oxford: Blackwell Scientific Publications; 1989. p 73-104.
9. Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H. Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification. J Clin Psychopharmacol 1988; 8: 441-2.
10. Chen MX, Jin GZ. Role of d-tetrahydropalmatine in the inhibition of dopamine and serotonin uptake of synaptosomes in the rat brain. Chin J Physiol Sci 1996; 12: 25-30.
11. Jin GZ. (-)-Tetrahydropalmatine and its analogues as new dopamine receptor antagonists. TIPS 1987; 8: 81-2.
12. Ge XQ, Zhang HQ, Zhou HZ, Xu ZG, Bian CF. Experimental study of tetrahydroprotoberberines inhibiting morphine withdrawal syndromes. Chin J Drug Depend 1999; 8: 178-84.
13. Jin GZ. Discoveries in the voyage of Corydalis reseach. Shanghai: Shanghai Scientific & Technical Publishers; 2001. p351-2.
14. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 1991; 16: 223-44.
15. Kalivas PW, Duffy P. Sensitization to repeated morphine injection in the rat: possible involvement of A 10 dopamine neurons. J Pharmacol Exp Ther 1987; 241: 204-12.
16. Vezina P, Stewart J. The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine. Brain Res 1989; 499: 108-20.
17. Scheel-Kruger J. Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. Acta Neuron Scand 1986; Suppl 107: 1-54.
18. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci 1993; 13: 266-75.
19. Magnus-Ellenbroek B, Havemann-Reinecke U. Morphine-induced hyperactivity in rats-a rebound effect? Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 635-42.
20. Kuribara H. Modification of morphine sensitization by opiod and dopamine receptor antagonists: evaluation by studying ambulation in mice. Eur J Pharmacol 1995; 275: 251-8.
21. Martin MI, Lizasoain L, Leza JC. Calcium channel blockers: effects on morphine-induced hyperactivity. Psychopharmacol 1990; 101: 267-70.
22. 2+ channel antagonists on morphine analgesia, tolerance and dependence and on blood pressure in the rat. Eur J Pharmacol 1998; 352: 189-97.
23. Pucilowski O. Psychopharmacological properties of calcium channel inhibitors. Psychopharmacology 1992; 109: 12-29.
24. Argiolas A, Melis MR, Gessa GL. Calcium channel inhibitors prevent apomorphine- and oxytocin-induced penile erection and yawning in male rats. Eur J Pharmacol 1989; 166: 515-8.
25. Czyrak A, Mogilnicka E, Maj J. Some central pharmacological effects of the calcium channel antagonist flunarizine. J Neural Transm Gen Sect 1990; 83: 179-88.
26. 2+ channel blockers inhibit the development but not the expression of sensitization to morphine in mice. Eur J Pharmacol 2003; 467: 145-50.
27. Huang K, Dai GZ, Li XH, Fan Q, Cheng L, Feng YB, et al. Blocking L-calcium current by l-tetrahydropalmatine in single ventricular myocyte of guinea pigs. Acta Pharmacol Sin 1999; 20: 907-11.
28. Li XT, Wang YL, Wang JX, Yang SJ. Effects of tetrahydroprotoberberines on cytosolic free calcium in cultured rat single myocardial cells. Acta Pharm Sin 1995; 30: 567-72.
29. Sun F, Li DX. Effects of l-tetrahydropalmatine on isolated rabbit arterial strips. Acta Pharmacol Sin 1989; 10: 30-3.